CTOs on the Move

Autonomic Technologies

www.autonomictechnologies.com

 
Welcome. Autonomic Technologies, Inc. (ATI) is a medical device company focused on the development and commercialization of innovative therapies for the treatment of severe headache. The company`s initial product, the ATI Neurostimulation System, is approved in Europe for the treatment of cluster headache. The ATI Neurostimulation System was voted #2 among the Cleveland Clinic’s top 10 medical innovations for 2013, and Autonomic Technologies was named one of FierceMedicalDevices’ Fierce 15 most promising privately held medical device and diagnostics companies in the world.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Autonomic Technologies raised $25M on 05/22/2015

Similar Companies

AllMed

AllMed Healthcare Management is a utilization management and independent review organization providing comprehensive nurse and physician review solutions to payer and provider organizations nationwide. Our clients include leading health plans, medical management organizations, TPAs, disability carriers, hospital groups and ambulatory surgery centers. Services are deployed through PeerPoint, AllMed`s state-of-the-art medical review portal.

NAMSA North American Science Associates

NAMSA North American Science Associates, Inc. is a Northwood, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Wings International

Medical Wings International is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

A Bay Area Vital Link Inc

A Bay Area Vital Link Inc is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allergen Research

Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.